- Home
- NXTC vs TNON Comparison
NXTC vs TNON Comparison
Compare NXTC & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- TNON
- Stock Information
- Founded
- NXTC 2015
- TNON 2012
- Country
- NXTC United States
- TNON United States
- Employees
- NXTC N/A
- TNON N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- TNON Medical Specialities
- Sector
- NXTC Health Care
- TNON Health Care
- Exchange
- NXTC Nasdaq
- TNON Nasdaq
- Market Cap
- NXTC 12.8M
- TNON 10.6M
- IPO Year
- NXTC 2019
- TNON 2022
- Fundamental
- Price
- NXTC $5.12
- TNON $1.39
- Analyst Decision
- NXTC Strong Buy
- TNON Strong Buy
- Analyst Count
- NXTC 2
- TNON 3
- Target Price
- NXTC $25.50
- TNON $11.67
- AVG Volume (30 Days)
- NXTC 318.4K
- TNON 13.6M
- Earning Date
- NXTC 08-07-2025
- TNON 08-13-2025
- Dividend Yield
- NXTC N/A
- TNON N/A
- EPS Growth
- NXTC N/A
- TNON N/A
- EPS
- NXTC N/A
- TNON N/A
- Revenue
- NXTC N/A
- TNON $2,947,000.00
- Revenue This Year
- NXTC N/A
- TNON $39.03
- Revenue Next Year
- NXTC N/A
- TNON $66.24
- P/E Ratio
- NXTC N/A
- TNON N/A
- Revenue Growth
- NXTC N/A
- TNON N/A
- 52 Week Low
- NXTC $2.69
- TNON $0.85
- 52 Week High
- NXTC $19.80
- TNON $15.79
- Technical
- Relative Strength Index (RSI)
- NXTC 48.99
- TNON 56.99
- Support Level
- NXTC $4.75
- TNON $1.33
- Resistance Level
- NXTC $5.23
- TNON $1.74
- Average True Range (ATR)
- NXTC 0.31
- TNON 0.22
- MACD
- NXTC 0.02
- TNON 0.01
- Stochastic Oscillator
- NXTC 53.28
- TNON 27.81
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.